Sean A Fletcher, Maximilian Pallauf, Emelia K Watts, Kara A Lombardo, Jack A Campbell, Michael E Rezaee, Morgan Rouprêt, Stephen A Boorjian, Aaron M Potretzke, M Reza Roshandel, Guillaume Ploussard, Hooman Djaladat, Alireza Ghoreifi, Andrea Mari, Riccardo Campi, Zine-Eddine Khene, Jay D Raman, Eiji Kikuchi, Michael Rink, Firas Abdollah, Joost L Boormans, Kazutoshi Fujita, David D'Andrea, Francesco Soria, Alberto Breda, Jean Hoffman-Censits, David J McConkey, Shahrokh F Shariat, Benjamin Pradere, Nirmish Singla
BACKGROUND AND OBJECTIVE: Growing evidence supports the use of neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC). However, the implications of residual UTUC at radical nephroureterectomy (RNU) after NAC are not well characterized. Our objective was to compare oncologic outcomes for pathologic risk-matched patients who underwent RNU for UTUC who either received NAC or were chemotherapy-naïve. METHODS: We retrospectively identified 1993 patients (including 112 NAC recipients) who underwent RNU for nonmetastatic, high-grade UTUC between 1985 and 2022 in a large, international, multicenter cohort...
January 22, 2024: European Urology Oncology